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The characteristics of HIV-associated ITP were documented prior to the HAART era, and the optimal treatment beyond HAART
is unknown. We performed a review of patients with HIV-associated ITP and at least one platelet count < 20×109/L since January
1996. Of 5290 patients in the BC Centre for Excellence in HIV/AIDS database, 31 (0.6%) had an ITP diagnosis and platelet count
< 20 × 109/L. Initial ITP treatment included IVIG, n = 12; steroids, n = 10; anti-RhD, n = 8; HAART, n = 3. Sixteen patients
achieved response and nine patients achieved complete response according to the International Working Group criteria. Median
time to response was 14 days. Platelet response was not signiﬁcantly associated with treatment received, but complete response
was lower in patients with a history of injection drug use. Complications of ITP treatment occurred in two patients and there
were four unrelated deaths. At a median followup of 48 months, 22 patients (71%) required secondary ITP treatment. This is to
our knowledge the largest series of severe HIV-associated ITP reported in the HAART era. Although most patients achieved a safe
platelet count with primary ITP treatment, nearly all required retreatment for ITP recurrence. New approaches to the treatment
of severe ITP in this population are needed.
1.Introduction
An association between immune thrombocytopenia (ITP)
and the acquired immune deﬁciency syndrome (AIDS) was
ﬁrst recognized in 1982 [1]. Prior to the advent of highly
activeantiretroviraltherapy(HAART),theincidenceofHIV-
associated thrombocytopenia was estimated at 10–30%, and
thrombocytopenia was the initial manifestation of HIV in
approximately 10% of cases [2, 3]. The incidence varied
according to the deﬁnition of thrombocytopenia and the
characteristics of the baseline population; for example, it
was more common in HIV-infected intravenous drug users
(IDUs) compared to HIV-infected men who have sex with
men [2]. Although thrombocytopenia may occur at any
time during the course of HIV infection, the incidence
generally correlates with the degree of immunosuppression
and is more prevalent in individuals with clinical AIDS
[4–6].
In the initial reports of HIV-associated ITP, throm-
bocytopenia generally responded well to treatment with
corticosteroids or splenectomy [7–9]. Subsequent studies
showed improved platelet counts with antiretroviral therapy,
in particular HAART [10, 11], and this is now the initial
treatment of choice for patients with HIV-associated ITP
[12]. Since the era of widespread use of HAART, there
have been no published studies describing the incidence or
clinical features of HIV-associated ITP [3]. Further, there are
minimal data on the safety of various treatment regimens in
HIV-positive patients, and the optimal treatment approach
to HIV-associated ITP beyond HAART is unknown [3, 13].
The objectives of this study were to determine the frequency
of severe HIV-associated ITP in the HAART era and to2 Advances in Hematology
describe the clinical features, treatment, and outcomes of
patients diagnosed with severe HIV-associated ITP in the
HAART era.
2. Methods
We searched the BC Centre for Excellence in HIV/AIDS
(CFE)databasetoidentifypatientswithHIVwhohadatleast
one platelet count <100 × 109/L since January 1996; the year
HAART use was widely adopted in British Columbia. For
this paper, we chose to focus on patients with severe HIV-
associated ITP. Although the International Working Group
(IWG) deﬁnition of severe ITP includes only patients with
clinically relevant bleeding [14], since it would be impossible
to identify this group of patients retrospectively from our
database, we deﬁned severe thrombocytopenia as at least
one platelet count <20 × 109/L. We chose this approach
because, at our institution, these patients are routinely
referred to hematology and generally require treatment,
whereaspatientswithHIV-associatedITPandhigherplatelet
counts are usually managed by their primary care physician
or HIV specialist. We reviewed all charts from patients with a
plateletcount<20 ×109/L.Fortheanalysis,weincludedonly
patients with a diagnosis of HIV-associated ITP made by a
hematologist. Patients were excluded if they had pancytope-
nia, were taking medications that cause thrombocytopenia,
had another documented cause of thrombocytopenia, or did
not have documentation of assessment by a hematologist.
Coinfection with hepatitis B or C was deﬁned as serologic
evidenceofhepatitisBorCinfectionpriortooratthetimeof
ITPdiagnosis.Chronicliverdiseasewasdeﬁnedasradiologic
or laboratory evidence of chronic liver dysfunction prior to
the time of ITP diagnosis.
The IWG criteria were used to assess response, with
complete response (CR) deﬁned as a platelet count ≥100 ×
109/L, response (R) deﬁned as a platelet count ≥30 × 109/L
and at least a two-fold increase from baseline count and
absence of bleeding, no response (NR) deﬁned as failure to
achieve a platelet count ≥30 × 109/L or less than a two-
fold increase from baseline, or ongoing bleeding, and loss of
response deﬁned as recurrent platelet count <30 × 109/L or
<two-fold greater than baseline or bleeding [14]. Descriptive
statistics were used to summarize the data. Response rates
were compared using the Fischer’s exact test, using SPSS for
Windows, version 18.0.
3. Results
Of 5290 patients in the CFE database since 1996, 1357 (26%)
had at least one platelet count <100 × 109/L, 417 (8%) had
at least one platelet count <50 × 109/L, 151 (3%) had at least
one platelet count ≤20 × 109/L, and 31 patients (0.6%) were
diagnosed with HIV-associated ITP and had a platelet count
≤20 × 109/L, see Figure 1.
3.1.ClinicalCharacteristics. Theclinicalcharacteristicsofthe
31 patients diagnosed with severe HIV-associated ITP are
shown in Table 1. The median age at ITP diagnosis was 37
Total patients
Plt < 100 ×109/L
1357 (26%)
151 (3%)
ITP
31 (0.6%)
N = 5290
Plt ≤ 20 ×109/L
Figure 1: Incidence of thrombocytopenia in HIV-infected individ-
uals in the HAART era.
(range 27–66) years. The median platelet count was 10 ×
109/L (range 2–19 × 109/ L ) ,m e d i a nh e m o g l o b i nw a s1 2 9
(34–165)g/L, and median neutrophil count was 2.5 (1.0–
17.0) × 109/L. Seventeen patients (55%) presented with
clinical bleeding and four (13%) required packed red blood
celltransfusion.Comorbiditiesincludedchronicliverdisease
in ﬁve patients, chronic renal failure in two, seizure disorder
in two, and chronic obstructive pulmonary disease, Crohn’s
disease, type 2 diabetes mellitus, peripheral vascular disease,
phenylketonuria, prostate cancer, psychiatric disorder, and
pulmonaryhypertensioneachinonepatient.Twelvepatients
had hepatitis C and four patients had hepatitis B coinfection.
Treatment for the coinfections was not documented. Six
patients had a bone marrow aspirate and biopsy and all
showed increased megakaryocyte numbers, consistent with
a diagnosis of ITP. Of 29 patients with a CD4 count
documented at the time of severe ITP diagnosis, the median
CD4 was 290 (20–600) cells/µL. Four patients had an HIV
viral load documented at the time of severe ITP diagnosis,
and it was >100000copies/mL in two patients, 92730 and
90copies/mL in each of the other patients. Ten patients were
receiving HAART at the time of severe ITP diagnosis. Of
these,threehadaCD4<200 cells/µL,suggestingsuboptimal
therapy or adherence to therapy.
3.2. Primary ITP Treatment. Treatments received at the ﬁrst
episode of a platelet count <20 × 109/L are listed in Table 2.
Thirteen patients received HAART as part of their primary
ITP treatment, including the ten patients who were receiving
HAART prior to the diagnosis of ITP. Of the 18 patients who
did not receive HAART with primary ITP therapy, 12 had a
CD4 count >200 cells/µL and 13 had IDU as their risk factor
for HIV, including the six patients with a CD4 count <200
cells/µL.
Overall, 25 patients achieved a CR or R according to the
IWG criteria (see Figure 2). The median platelet responseAdvances in Hematology 3
Table 1: Clinical characteristics of 31 patients with HIV-associated
ITP diagnosed since 1996.
Characteristic N
Age at ITP presentation (years)
≤40 12
>40 19
Gender
Male 25
Female 5
Transgender (MF) 1
Platelet count (×109/L)
≤10 15
>10 16
Hemoglobin at ITP diagnosis (g/L)
<90 4
>90 24
Clinical bleeding 17
Site of bleeding
Epistaxis 14
Menorrhagia 3
Gingival bleed 2
Gastrointestinal bleed 1
Hemoptysis 1
HIV risk factor (N = 26)
Sexual 10
IDU 16
CD4 at ITP diagnosis (cells/µL, N = 29)
<200 8
≥200 21
Prior AIDS1 5
Coinfections
Hepatitis B 4
Hepatitis C 12
Receiving HAART2 at ITP diagnosis
No 20
Yes 10
Comorbidities 15
1Mycobacterium avian complex, n = 2; Pneumocystis jirovecii pneumonia,
n = 2; anal condylomata, n = 1.
2HAART was 1 nucleoside analog (NA), 1 protease inhibitor, and either a
2nd NA or a nonnucleoside reverse transcription inhibitor.
within 30 days was 58 (5–322) × 109/L and the median time
to R was 14 (1–3192) days.
3.3. Secondary ITP Treatment. At a median followup of 48
(0.2–138.5) months, 22 patients (71%) hada lossof response
andrequiredsecondaryITPtreatmentforarecurrentplatelet
count <20 × 109/L. The median platelet count at recurrent
ITP diagnosis was 10 (5–20) × 109/L. The median time
to loss of response was 39 (8–858) days. Of 13 patients
that received HAART with their primary treatment, seven
had recurrent ITP. Six of seven patients who did not
relapse received HAART with their primary treatment, three
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Figure 2: Maximum platelet response.
received HAART as treatment for ITP, and three were on
HAART prior to ITP diagnosis.
Secondary treatment included IVIG in nine patients,
anti-RhD in six patients, steroids in four patients, splenec-
tomy in three patients, and initiation of HAART in one
patient. The median platelet response within 30 days of the
initiation of secondary ITP treatment was 42 (21–198) ×
109/L (n = 19). Eleven patients achieved R and eight patients
achieved CR to secondary treatment. The median time to
response was seven (2–280) days. All three patients who
underwent splenectomy achieved a normal platelet count
which was sustained at followup of 14, 58, and 123 months.
3.4. Predictors of ITP Response. The probability of response
to primary ITP treatment did not appear to be signiﬁcantly
inﬂuenced by the choice of treatment or by the number
of treatments received; however, ﬁrm conclusions regarding
this are limited by small patient numbers. When considering
patient characteristics, patients with a history of IDU were
less likely to achieve a CR (P = 0.04, N = 30). We did
not ﬁnd a signiﬁcant diﬀerence in any patient characteristics
between patients whoachievedRcomparedtothose whodid
not, likely because the number of patients with NR was so
small. Loss of response did not appear to be associated with
any particular patient or treatment characteristic.
3.5. Complications of Treatment. Complications of treatment
were psychiatric eﬀects of steroids in one patient and
postsplenectomy fever and hematoma in one patient. There
were no opportunistic infections; however, seven patients
received prophylaxis for Pneumocystis jirovecii pneumonia
(PCP), including ﬁve patients who received septra, and two
patients who received dapsone.
3.6. Survival and Causes of Death. There were four deaths
and causes were variceal bleed in two patients, Evan’s
syndrome and hepatic failure in one patient, and advanced
HIV in one patient. Both patients who died of variceal
bleeding had a platelet count >50 × 109/L at most recent
followup, a history of IDU, hepatitis C coinfection, and
hepatic cirrhosis. The patient who died of Evan’s syndrome
hadsexualcontactashisriskfactorforHIVandnohistoryof
hepatitis C or chronic liver disease. He was receiving HAART
priortodeathandthemostrecentCD4was260 cells/µL.His4 Advances in Hematology
Table 2: Treatment regimens for HIV-associated ITP and responses achieved.
Treatment Dose N Bleeding (%) R + CR (%) CR (%) Median time to R
in days (range) Relapse (%)
IVIG 1g/kg/day × 2 days 7 6 (86) 5 (71) 4 (57) 4 (3–9) 6 (86)
Anti-D 2.4–4mg 7 2 (29) 6 (86) 0 (0) 14 (1–61) 4 (57)
Prednisone 50–85mg daily 4 2 (50) 4 (100) 1 (25) 4.5 (3–13) 3 (75)
HAART alone
∗See footnote 4 1 (25) 3 (75) 1 (25) 267 (1–1379) 3 (75)
IVIG + 1g/kg/day × 2 days 5 4 (80) 5 (100) 3 (60) 11 (3–16) 3 (60)
Prednisone 50–70mg
Anti-D + 1.3mg 1 1 (100) 1 (100) 0 (0) 22 1 (100)
Prednisone 40mg daily
HAART +
∗∗See footnote 9 5 (56) 8 (89) 5 (56) 13.5 (3–22) 4 (44)
Other therapy
None 3 0 (0) 2 (67) 2 (67) 696 (26–3192) 2 (67)
∗HAART was 1 nucleoside analog (NA), 1 protease inhibitor, and either a 2nd NA or a nonnucleoside reverse transcription inhibitor.
∗∗Other therapy was IVIG, prednisone, or anti-D in the doses listed above. Patients in this group were also included in the groups above with patients who
received the respective therapies without HAART.
platelet count on the day of death was 8 × 109/L. The patient
who died of advanced HIV had a history of coinfection with
hepatitisC,PCP,TB,andpulmonaryhypertension.Themost
recent platelet count was 23 × 109/L nine days before her
death.
4. Discussion
In this study, although the incidence of thrombocytopenia
in HIV-infected individuals was high (26%), the incidence
of severe HIV-associated thrombocytopenia was only 0.6%.
These results are similar to those of studies performed in
the era prior to the widespread use of HAART, in which
the incidence of platelet count less than 150 × 109/L was
10–30% in HIV-infected individuals, and the incidence of a
platelet count less than 50 × 109/L was 1.5–9% [2, 4, 15].
Approximately two-thirds of patients in our study had a
CD4 count over 200cells/µL. Although this seems contrary
to previous studies that showed an increased incidence and
severity of thrombocytopenia with lower CD4 counts [4–
6], in our study, the higher number of patients with CD4
count greater than 200cells/µL is most likely a reﬂection of
the composition of the baseline population in the HAART
era. Importantly, our study shows that control of HIV
infection alone is not suﬃcient to prevent ITP in all
patients.
In our population in the HAART era, more patients with
severe thrombocytopenia had a history of IDU than sexual
contact as their HIV risk factor, consistent with ﬁndings in
the pre-HAART era [2, 8, 15]. We also found that patients
withahistoryofIDUhadinferiorplateletresponse.Potential
reasons for this association include higher rates of coinfec-
tion with hepatitis C in the IDU population, lower rates
of compliance with HAART and other treatments, direct
toxicity from the injection drugs, or from contaminating
substances mixed in the drugs. In our study the type of drugs
and the potential for contaminating substances were not
documented, but we did ﬁnd a high incidence of coinfection
with hepatitis C virus, which is consistent with the ﬁndings
from prior studies [2, 16].
Nearly all patients in this study achieved a safe platelet
count with primary ITP treatment. The rates of response to
steroids, IVIG, and anti-D were similar to those previously
reported and we were unable to show a signiﬁcant diﬀerence
in response according to treatment received. In a study of
injection drug users with HIV-associated ITP in the pre-
HAART era, Landonio showed response rates of 65% and
80% to IVIG and anti-D [8]. Walsh found that 16 of 17
men who have sex with men with ITP in the pre-HAART era
responded to prednisone [7].
Although there were few treatment complications in our
study, most patients (71%) required secondary treatment for
loss of response, including seven of 13 patients receiving
HAART with initial ITP therapy. This is consistent with
ﬁndings from the study by Landonio, in which only four
of 17 patients treated with IVIG had sustained remissions,
and all patients treated with steroids had recurrent ITP after
discontinuation of initial therapy [8]. In a randomized cross-
over study of nine patients with severe HIV-associated ITP,
Scaradavou found the median duration of response wasAdvances in Hematology 5
19 days following treatment with IVIG and 41 days following
anti-RhD [17].
As with primary treatment for ITP, most patients in
our study who received secondary treatment for recurrent
thrombocytopenia achieved a platelet count >30 × 109/L.
Although splenectomy appeared to be safe and eﬀective
in the three patients who underwent this treatment, given
the lifelong increased risk of severe infections, we have
reservations about using this therapy in patients with
HIV, particularly those with hepatitis C coinfection. In a
series of 68 patients who underwent splenectomy for HIV-
associated ITP in the pre-HAART era, 82% had sustained
platelet counts >50 × 109/L and there was no signiﬁcant
diﬀerence in progression to AIDS or survival compared to
patients without splenectomy. However, two patients died
of fulminant septic shock and two others presented with
Streptococcus pneumoniae meningitis [18].
This is to our knowledge the largest series of patients
with severe HIV-related ITP reported since the availability
of HAART, and one strength of the study is the substantial
length of followup, a median of four years. The main
limitation of our study is its retrospective nature. Because
of this, small patient numbers, and many variables in this
patient population, we cannot make deﬁnitive conclusions
about the eﬃcacy of one treatment compared to another.
In addition, since the study was conducted at a single
institution, the results may not apply to other populations.
Furthermore, since we chose only to include patients with
severe HIV-associated ITP who were referred to hematology,
there is selection bias and the ﬁndings are not necessarily
applicable to patients with mild or moderate thrombocy-
topenia. Finally, none of the patients in our study were
treated with rituximab or thrombopoietin receptor agonists;
therefore, we cannot comment on the safety or eﬃcacy
of these newer agents in the treatment of HIV-associated
ITP.
5. Conclusions
HIV-associated ITP remains an important clinical problem
in the era of the widespread use of HAART. Although most
patients respond to primary ITP treatment and there are few
treatment-related complications, nearly all patients require
retreatment for recurrent ITP. Inferior response to treatment
was associated with a history of IDU. New approaches to the
treatment of HIV-associated ITP in this patient population
are needed.
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